MOORESTOWN, N.J., May 11, 2021 /PRNewswire/ -- Tabula Rasa
HealthCare, Inc. ("TRHC") (NASDAQ: TRHC), a leading healthcare
technology company advancing the safe use of medication, and
Regence Health Plans today announced the results of a
simulation-based clinical study which demonstrates that TRHC's
MedWise® medication risk score can be used to assess
drug safety without exposing real people to actual harm.
The study, published online in Clinical and Translational
Science, used TRHC's proprietary MedWise medications safety
technology to virtually assess the potential risk of adverse drug
events (ADEs) when adding repurposed drugs for COVID-19 treatment
to the individual medications of a large-scale population. The
results demonstrate that medication risk scores could be used to
effectively assess drug safety before exposing patients to
repurposed drugs.
"Through this innovative simulation we have demonstrated the
value of our MedWise technology as part of a blueprint to assess
the safety of newly prescribed repurposed drugs without exposing
real patients to potential harm," said TRHC Chairman and CEO
Calvin H. Knowlton, PhD. "By
partnering with Regence Health Plans, we have confirmed a powerful
preemptive tool to identify individuals at higher risk of adverse
drug events, to foresee types of potential risks, and to pin-point
drugs to be monitored on an individual level."
The simulated risk assessment examined de-identified medical
information from approximately 500,000 Medicare and commercially
insured Regence Health Plan members. Researchers determined each
person's baseline MedWise Risk Score™ (MRS) and simulated the
addition of five drugs repurposed for COVID-19 treatment. The
change in the MedWise Risk Score was used as a predictive tool to
assess the risk of adverse drug events associated with repurposed
drugs for COVID-19.
"Using a simulation-based approach, we are able to apply
scientific data on the drugs' mechanisms and metabolisms to
determine how these drugs would alter a patient's medication risk
score—without putting the patients at risk," said Veronique Michaud, Chief Operating Officer, TRHC
Precision Pharmacotherapy Research and Development Institute. "We
can use this data to identify patients at higher risk of adverse
drug events from large populations. Once identified, our TRHC
MedWise Advisor services can provide appropriate individual
recommendations to mitigate risk of ADEs."
"We are very pleased to be a part of this novel simulation-based
clinical study," said Matthew
Hafermann, a Regence's Clinical Pharmacist. "The simulation
strategy using a medication risk score represents an innovative
approach to furthering patient safety by preemptively estimating
the risk of adverse drug events."
About Tabula Rasa HealthCare
Tabula Rasa HealthCare (TRHC) provides medication safety
solutions that empower healthcare professionals and consumers to
optimize medication regimens, combatting medication overload and
reducing adverse drug events – the fourth leading cause of death in
the US. TRHC's proprietary technology solutions, including
DoseMeRx™ and MedWise®, improve patient outcomes, reduce
hospitalizations, and lower healthcare costs. TRHC's extensive
clinical tele-pharmacy network improves care for patients
nationwide. Its solutions are trusted by health plans and
pharmacies to help drive value-based payments. For more
information, visit TRHC.com.
About Regence
Regence serves approximately 3.3 million people through its
health plans in Idaho,
Oregon, Utah, and Washington. Each Regence health plan is a
nonprofit independent licensee of the Blue Cross and Blue Shield
Association. Regence is part of a family of companies dedicated to
transforming health care by delivering innovative products and
services that change the way consumers nationwide experience health
care. For more information, please visit regence.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/new-study-predicts-risks-of-drug-interactions-without-exposing-patients-to-harm-301287900.html
SOURCE Tabula Rasa HealthCare, Inc.